Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2022 Earnings Call Transcript
Editas Medicine reported Q4 2022 earnings, highlighting clinical progress with EDIT-301 for sickle cell disease and beta thalassemia, strategic shifts towards in-vivo gene editing, and financial stability extending into 2025. The company aims to advance its gene editing technologies and clinical trials, focusing on delivering transformative medicines.
Reference News
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2022 Earnings Call Transcript
Editas Medicine reported Q4 2022 earnings, highlighting clinical progress with EDIT-301 for sickle cell disease and beta thalassemia, strategic shifts towards in-vivo gene editing, and financial stability extending into 2025. The company aims to advance its gene editing technologies and clinical trials, focusing on delivering transformative medicines.